The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Dr. Anelyssa D'Abreu, an associate professor of neurology in UVA's School of Medicine who specializes in geriatric neurology, talked with UVA Today about the newest study and shared ways people can ...

Researchers at the University of Kentucky are in on a clinical trial on the use of medical cannabis for late-stage dementia patients. As research continues, those involved say this would be a game ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...